| Drug General Information |
| Drug ID |
D06GJO
|
| Former ID |
DNC005640
|
| Drug Name |
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H14N2O2
|
| Canonical SMILES |
COC1=CC=CC=C1NC2=NC=C(O2)C3=CC=CC=C3
|
| InChI |
1S/C16H14N2O2/c1-19-14-10-6-5-9-13(14)18-16-17-11-15(20-16)12-7-3-2-4-8-12/h2-11H,1H3,(H,17,18)
|
| InChIKey |
DLHCYJIQXKETIN-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[1]
|
|---|
| mRNA of VEGFR1 |
Target Info |
Inhibitor |
[1]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesionhsa04014:Ras signaling pathway
|
|
HIF-1 signaling pathway
|
|
Endocytosis
|
|
Focal adhesion
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
|
VEGF signaling pathway
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
TNFalpha Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endotheliumglypican_1pathway:Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
S1P3 pathway
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2hif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferation
|
|
WikiPathways
|
Signaling by VEGFWP306:Focal Adhesion
|
|
Signaling by VEGF
|
|
AngiogenesisWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Angiogenesis
|
| References |
| REF 1 | J Med Chem. 2005 Mar 10;48(5):1610-9.Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
|---|
